Investment briefing

Full year 2023 report on the state of longevity investment: the numbers, the sectors, the top deals, the key players and the outlook for 2024:
Annual longevity investment report 2023
Interim data release: November 2023:
Longevity Clinics Survey 2023
Read now
Edging ahead in Q3 but still held back:
Q3 2023: longevity investment report
Read now
Edging ahead in Q2 but still held back:
Q2 2023: longevity investment report
Read now
Investment review for January to March 2023. “If you’re going through hell, keep going.” Winston Churchill:
Q1 2023: longevity investment report
Read now
Full year 2022 report on the state of longevity investment: the numbers, the sectors, the top deals, the key players and the outlook for 2023:
Annual longevity investment report 2022
Read now
Disease management to disease modification – removing plaque to undo atherosclerosis:
Atherosclerosis
Read now
Delaying the menopause to increase women’s healthspan:
Reproductive longevity
Read now
Leading a new era of personalised, preventative health and optimal aging:
Longevity diagnostics
Read now
Supplementing your Longevity supplement knowledge:
Longevity supplements
Read now
Managing senescent cells to drive human longevity:
Senotherapeutics
Read now

News

Asceneuron bags $100m to advance tau-targeting Alzheimer’s drug into Phase 2 clinical trial

Company’s small molecule OGA inhibitors have shown potential to improve protein aggregation

Ani.VC out of the traps with $35 million fund for pet longevity

Early-stage fund will back innovative startups in Europe, Asia and the US

OpenAI Startup Fund and Thrive Global launch AI health coaching venture

Leveraging generative AI, Thrive AI Health seeks to improve healthspan and lifespan

HepaRegenix lands €15m to advance liver regeneration drug into clinical trials

Company to commence clinical trials of MKK4 inhibitor shown to induce liver